Our group has recently initiated a clinical trial testing a humanized OX40 agonist (MEDI0562) in the neoadjuvant setting in HNSCC and melanoma patients, which will allow us to assess the agonist activity of an anti-OX40 antibody independent of anti-drug immune responses. This evidence concerns the gene TNFRSF4 and melanoma.